ZIVO Bioscience, Inc. (ZIVO)
- Previous Close
13.99 - Open
13.99 - Bid 11.00 x 10000
- Ask 14.98 x 10000
- Day's Range
13.99 - 13.99 - 52 Week Range
5.51 - 22.15 - Volume
121 - Avg. Volume
487 - Market Cap (intraday)
53.351M - Beta (5Y Monthly) 0.04
- PE Ratio (TTM)
-- - EPS (TTM)
-4.88 - Earnings Date Aug 12, 2025 - Aug 18, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
ZIVO Bioscience, Inc., together with its subsidiaries, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. It offers poultry gut health, avian influenza, bovine mastitis, canine joint health, human immune modification, human functional food ingredients, algal biomass for human food, and biomass for supporting skin health and anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Troy, Michigan.
www.zivobioscience.comRecent News: ZIVO
View MorePerformance Overview: ZIVO
Trailing total returns as of 6/13/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ZIVO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ZIVO
View MoreValuation Measures
Market Cap
53.35M
Enterprise Value
53.81M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
393.52
Price/Book (mrq)
--
Enterprise Value/Revenue
442.87
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-948.38%
Return on Equity (ttm)
--
Revenue (ttm)
121.5k
Net Income Avi to Common (ttm)
-16.32M
Diluted EPS (ttm)
-4.88
Balance Sheet and Cash Flow
Total Cash (mrq)
517.19k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-404.17k